Heparin, Heparan Sulphate, and Sepsis: Possible Novel Therapeutic Approaches

Authors

  • A. Sai Saranya Asso. Professor, DEPT OF Pharmaceutical Analysis, NARAYANA PHARMACY COLLEGE, CHINTHA REDDY PALEM, NELLORE Author
  • D. Mahidhar Reddy Asso. Professor, DEPT OF PHARMACEUTICS, NARAYANA PHARMACY COLLEGE, CHINTHA REDDY PALEM, NELLORE Author
  • Sk. Karimunnisa, Asst. Professor, DEPT OF PHARMACEUTICS, NARAYANA PHARMACY COLLEGE, CHINTHA REDDY PALEM, NELLORE Author
  • J. Surya Prakash Asst. Professor, DEPT OF Pharmacy Practice, NARAYANA PHARMACY COLLEGE, CHINTHA REDDY PALEM, NELLORE Author
  • Dr. M. SREENIVASULU PRINCIPAL, NARAYANA PHARMACY COLLEGE, CHINTHA REDDY PALEM, NELLORE Author

Keywords:

heparin, heparinmimetics, heparansulphate, sepsis, neutrophils, heparanase

Abstract

Sepsis is a potentially fatal overreaction to an infection in which the host's tissues and organs are damaged by an
overabundance of inflammation and immunological response. One of the main components of the cell surface glycocalyx is the
glycosaminoglycanheparan sulphate (HS).Cell surface HS is a target for the pro-inflammatory enzyme heparanase and controls a
number of sepsis pathways, including neutrophil recruitment and pathogen interactions with the host cell. A close structural cousin of
HS, heparin is a potent anticoagulant and antithrombotic used in medicine.Numerous studies have shown that heparin, which has a
significant negative charge and structural similarities to HS, might affect how sepsis-related events develop. Heparin's anticoagulant
action, however, restricts its ability to treat inflammatory disorders by increasing the risk of bleeding and other unfavourable side
effects.Heparin derivatives and mimetic compounds with decreased anticoagulant action have been developed since the anticoagulant
potency of heparin is mostly governed by a single well-defined structural characteristic. In the case of sepsis, such heparin mimics
may be useful as therapeutic medicines.

References

Rudd,K.E.;Johnson,S.C.;Agesa,K.M.;Shackelford,K. A.;Tsoi,D.;Kievlan,D.R.;Colombara,D.V.;Ikuta,K.S.; Kissoon,N.;Finfer,S.; et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: Analysis for the Global Burden of Disease Study.Lancet 2020, 395, 200–211. [CrossRef] [PubMed]

Singer, M.; Deutschman, C.S.; Seymour, C.W.; Shankar-Hari, M.; Annane, D.; Bauer, M.; Bellomo, R.; Bernard, G.R.; Chiche, J.D.; Coopersmith, C.M.; et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). J. Am. Med. Assoc. 2016, 315, 801–810. [CrossRef] [PubMed]

Giustozzi,M.;Ehrlinder,H.;Bongiovanni,D.;Borova c,J.A.;Guerreiro,R.A.;Ga˛secka,A.;Papakonstantin ou,P.E.;Parker,W.A.E. Coagulopathy and sepsis: Pathophysiology, clinical manifestations and treatment.Blood Rev.2021,50, 100864.[CrossRef] [PubMed]

Wada, H.; Thachil, J.; Di Nisio, M.; Mathew, P.; Kurosawa, S.; Gando, S.; Kim, H.K.; Nielsen, J.D.; Dempfle, C.E.; Levi, M.; et al. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines.J. Thromb. Haemost. 2013, 11, 761– 767. [CrossRef] [PubMed]

Iba, T.; Arakawa, M.; Di Nisio, M.; Gando, S.; Anan, H.; Sato, K.; Ueki, Y.; Levy, J.H.; Thachil, J. Newly Proposed Sepsis-Induced CoagulopathyPrecedesInternationalSocietyonThro mbosisandHaemostasisOvert- DisseminatedIntravascularCoagulation andPredictsHighMortality. J.IntensiveCareMed. 2020,35,643–649. [CrossRef]

Iba,T.;Umemura,Y.;Wada,H.;Levy,J.H.RolesofCo agulationAbnormalitiesandMicrothrombosisinSeps is: Pathophysiology, Diagnosis,andTreatment. Arch.Med.Res.2021,52,788–797. [CrossRef]

Jarczak,D.;Kluge,S.;Nierhaus,A.Sepsis- PathophysiologyandTherapeuticConcepts.Front.Me d.2021,8,628302.[CrossRef]

Vagionas, D.; Papadakis, D.D.; Politou, M.; Koutsoukou, A.; Vasileiadis, I. Thromboinflammation in Sepsis and Heparin: A ReviewofLiteratureandPathophysiology. InVivo2022,36,2542–2557. [CrossRef]

Tree,J.A.;Turnbull,J.E.;Buttigieg,K.R.;Elmore,M.J. ;Coombes,N.;Hogwood,J.;Mycroft- West,C.J.;Lima,M.A.;Skidmore, M.A.; Karlsson, R.; et al. Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations.Br.J.Pharm.2021,178,626–635. [CrossRef]

Mycroft- West,C.J.;Su,D.;Pagani,I.;Rudd,T.R.;Elli,S.;Gandh i,N.S.;Guimond,S.E.;Miller,G.J.;Meneghetti,M.C. Z.;Nader, H.B.; et al.Heparin Inhibits Cellular Invasion by SARS-CoV-2:Structural Dependence of the Interaction of the Spike S1 Receptor- BindingDomainwithHeparin. Thromb.Haemost.2020,120,1700–1715. [CrossRef]

Sheehan, J.R.;Calpin,P.;Kernan,M.;Kelly,C.;Casey,S.;Murph y,D.;Alvarez- Iglesias,A.;Giacomini,C.;Cody,C.;Curley,G.;etal. The CHARTER-Ireland trial: Can nebulised heparin reduce acute lung injury in patients with SARS-CoV-2 requiring advanced respiratorysupportinIreland: Astudyprotocolandstatisticalanalysisplanforarando misedcontroltrial. Trials2022,23,774. [CrossRef]

Van Haren, F.M.P.; van Loon, L.M.; Steins, A.; Smoot, T.L.; Sas, C.; Staas, S.; Vilaseca, A.B.; Barbera, R.A.; Vidmar, G.; Beccari, H.; et al. Inhaled nebulised unfractionated heparin for the treatment of hospitalised patients with COVID-19: A multicentre case seriesof98patients.Br.J.Clin.Pharm.2022,88,2802– 2813.[CrossRef]

Van Haren, F.M.P.; Laffey, J.G.; Artigas, A.; Page, C.; Schultz, M.J.; Cosgrave, D.; McNicholas, B.; Smoot, T.L.; Nunes, Q.; Richardson, A.; et al. Can nebulised HepArin Reduce morTality and time to Extubation in patients with COVID-19 Requiring invasive ventilation Meta-Trial (CHARTER-MT): Protocol and statistical analysis plan for an investigator-initiated internationalmetatrialofprospectiverandomisedclinicalstudies.Br.J.Cl in.Pharm.2022,88,3272–3287.[CrossRef]

VanHaren,F.M.P.;Page,C.;Laffey,J.G.;Artigas,A.; Camprubi- Rimblas,M.;Nunes,Q.;Smith,R.;Shute,J.;Carroll,M. ;Tree,J.; etal.NebulisedheparinasatreatmentforCOVID- 19:Scientificrationaleandacallforrandomisedeviden ce.Crit.Care2020,24, 454.[CrossRef]

Mulloy, B.; Hogwood, J.; Gray, E.; Lever, R.; Page, C.P. Pharmacology of Heparin and Related Drugs.Pharm.Rev.2016, 68, 76–141.[CrossRef]

Wang,P.;Chi,L.;Zhang,Z.;Zhao,H.;Zhang,F.;Linhar dt,R.J.Heparin:Anolddrugfornewclinicalapplicatio ns.Carbohydr. Polym.2022, 295, 119818. [CrossRef]

Chen,D.Heparinbeyondanticoagulation.Curr.Res.Transl.Med.2021,69,103300.[Cro ssRef]

Cao,M.;Qiao,M.;Sohail,M.;Zhang,X.NonanticoagulantheparinderivativesforCOVID- 19treatment.Int.J.Biol.Macromol. 2023,226,974–981.[CrossRef]

Jiang,L.;Zhang,T.;Lu,H.;Li,S.;Lv,K.;Tuffour,A.;Z hang,L.;Ding,K.;Li,J.P.;Li,H.;etal.Heparinmimetic saspotential interventionforCOVID-19andtheirbiomanufacturing. Synth. Syst. Biotechnol. 2023,8,11–19. [CrossRef]

Wheeler,A.P.;Bernard,G.R.Treatingpatientswithsevere sepsis.N. Engl.J.Med.1999,340,207–214.[CrossRef]

Levi, M.; de Jonge, E.; van der Poll, T. Sepsis and disseminated intravascular coagulation.J. Thromb.Thrombolysis 2003, 16, 43–47.[CrossRef] [PubMed]

Strauss,R.;Wehler,M.;Mehler,K.;Kreutzer,D.;Koebni ck,C.;Hahn,E.G.Thrombocytopeniainpatientsintheme dicalintensivecare unit: Bleeding prevalence, transfusion requirements, and outcome. Crit. CareMed. 2002, 30, 1765–1771. [CrossRef] [PubMed]

Lee,K.H.;Hui,K.P.;Tan,W.C.Thrombocytopeniainse psis:Apredictorofmortalityintheintensivecareunit.Sin gap.Med.J. 1993,34,245–246.

Mavrommatis,A.C.;Theodoridis,T.;Orfanidou,A .;Roussos,C.;Christopoulou- Kokkinou,V.;Zakynthinos,S.Coagulation system and platelets are fully activated in uncomplicated sepsis.Crit.Care Med.2000, 28, 451–457.[CrossRef]

Francois, B.; Trimoreau, F.; Vignon, P.; Fixe, P.; Praloran, V.; Gastinne, H. Thrombocytopenia in the sepsis syndrome:Role of hemophagocytosisandmacrophagecolonystimulatingfactor. Am.J.Med.1997,103,114–120. [CrossRef]

Zimmerman, G.A.;McIntyre, T.M.;Prescott, S.M.;Stafforini, D.M. The platelet-activating factor signaling system and its regulatorsinsyndromesofinflammationandthrombos is. Crit.CareMed.2002,30,S294–S301. [CrossRef]

Zaid,Y.;Merhi,Y.ImplicationofPlateletsinImmuno- ThrombosisandThrombo-Inflammation. Front.Cardiovasc.Med.2022,9, 863846.[CrossRef]

Gray,E.;Cesmeli,S.;Lormeau,J.C.;Davies,A.B.;Lane, D.A.Lowaffinityheparinisanantithromboticagent.Thr omb.Haemost. 1994,71,203–207.

Periayah,M.H.;Halim,A.S.;MatSaad,A.Z.Mechanis mActionofPlateletsandCrucialBloodCoagulationPa thwaysin Hemostasis.Int.J.Hematol.Oncol.StemCellRes.201 7,11,319–327.

Versteeg,H.H.;Heemskerk,J.W.;Levi,M.;Reitsma,P. H.Newfundamentalsinhemostasis.Physiol.Rev.2013, 93,327–358. [CrossRef]

Krisinger,M.J.;Goebeler,V.;Lu,Z.;Meixner,S.C.;M yles,T.;Pryzdial,E.L.;Conway,E.M.Thrombingener atespreviously unidentifiedC5productsthatsupporttheterminalcom plementactivationpathway. Blood2012,120,1717– 1725. [CrossRef]

Mast,A.E.TissueFactorPathwayInhibitor:MultipleAntic oagulantActivitiesforaSingleProtein.Arter.Thromb.Vas c.Biol.2016, 36,9–14.[CrossRef]

Levi,M.;Poll,T.Coagulationinpatientswithsevereseps is.Semin.Thromb.Haemost.2015,41,9–15.[CrossRef]

Marietta, M.; Vandelli, P.; Mighali, P.; Vicini, R.; Coluccio, V.; D’Amico, R. Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): A structured summary of a study protocol. Trials 2020, 21, 574. [CrossRef]

Goligher, E.C.; Bradbury, C.A.; McVerry, B.J.; Lawler, P.R.; Berger, J.S.; Gong, M.N.; Carrier, M.; Reynolds, H.R.; Kumar, A.; Turgeon, A.F.; et al.Therapeutic Anticoagulation with Heparin in Critically Ill Patients with COVID-19.N.Engl. J.Med. 2021, 385,777–789. [CrossRef]

Spyropoulos, A.C.; Goldin, M.; Giannis, D.; Diab, W.; Wang, J.; Khanijo, S.; Mignatti, A.; Gianos, E.; Cohen, M.; Sharifova, G.; et al. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophy- laxisinHighriskHospitalizedPatientsWithCOVID-19: TheHEP- COVIDRandomizedClinicalTrial. J.Am. Med. Assoc. Intern. Med. 2021,181,1612–1620. [CrossRef]

Sholzberg,M.;Tang,G.H.;Rahhal,H.;AlHamzah, M.;Kreuziger,L.B.;Áinle,F.N.;Alomran,F.;Alayed, K.;Alsheef,M.;AlSumait, F.; et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unitadmission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ Clin. Res. Ed. 2021,375, n2400. [CrossRef]

Billett, H.H.; Reyes-Gil, M.; Szymanski, J.; Ikemura, K.; Stahl, L.R.; Lo, Y.; Rahman, S.; Gonzalez-Lugo, J.D.; Kushnir, M.; Barouqa, M.;etal. AnticoagulationinCOVID-19: EffectofEnoxaparin,Heparin,andApixabanonMorta lity. Thromb. Haemost. 2020,120, 1691–1699. [CrossRef]

D’Ardes,D.; Carrarini, C.; Russo, M.; Dono, F.; Speranza, R.; Digiovanni, A.; Martinotti, G.; Di Iorio, A.; Onofrj, M.; Cipollone, F.;etal.LowmolecularweightheparininCOVID- 19patientspreventsdeliriumandshortenshospitalizati on.Neurol.Sci.2021,42, 1527–1530. [CrossRef]

Miesbach, W.; Makris, M. COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation.Clin. Appl. Thromb./Hemost. 2020, 26, 1076029620938149. [CrossRef]

Mattioli, M.; Benfaremo, D.; Mancini, M.; Mucci, L.; Mainquà, P.; Polenta, A.; Baldini, P.M.; Fulgenzi, F.; Dennetta, D.; Bedetta,S.; et al. Safety of intermediate dose of low molecular weight heparin in COVID-19 patients.J.Thromb. Thrombolysis2021, 51, 286–292. [CrossRef] [PubMed]

Sadeghipour, P.; Talasaz, A.H.; Rashidi, F.; Sharif- Kashani, B.; Beigmohammadi, M.T.; Farrokhpour, M.; Sezavar, S.H.; Payande- mehr, P.; Dabbagh, A.; Moghadam, K.G.; et al. Effect of Intermediate- Dose vs Standard-Dose Prophylactic Anticoagulation on ThromboticEvents,ExtracorporealMembraneOxyge nationTreatment,orMortalityAmongPatientsWithC OVID-19Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. J.Am. Med. Assoc. 2021, 325, 1620–1630. [CrossRef]

Lopes,R.D.;deBarros,E.S.P.G.M.;Furtado,R.H.M.;Ma cedo,A.V.S.;Bronhara,B.;Damiani,L.P.;Barbosa,L.M. ;deAveiroMorata,J.; Ramacciotti, E.; de Aquino Martins, P.; et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospitalwith COVID-19 and elevated D-dimer concentration (ACTION): An open-label, multicentre, randomised, controlled trial.Lancet 2021, 397, 2253–2263. [CrossRef] [PubMed]

Di Castelnuovo, A.; Costanzo, S.; Antinori, A.; Berselli, N.; Blandi, L.; Bonaccio, M.; Cauda, R.; Guaraldi, G.; Menicanti, L.; Mennuni,M.;etal.Heparinin COVID- 19PatientsIsAssociatedwithReducedIn- HospitalMortality:TheMulticenterItalianCORIST Study. Thromb. Haemost. 2021, 121, 1054–1065. [CrossRef]

Fu,S.;Yu,S.;Wang,L.;Ma,X.;Li,X.Unfractionatedh eparinimprovestheclinicalefficacyinadultsepsispati ents: Asystematic review and meta-analysis. BMCAnesthesiol. 2022, 22, 28. [CrossRef]

Li,X.;Liu,Z.;Luo,M.;Xi,Y.;Li,C.;Wang,S.;Yang,R. Therapeuticeffectoflow-molecularweightheparinonadultsepsis:A meta-analysis. Ann.Palliat.Med.2021,10,3115–3127. [CrossRef]

Iba, T.; Miyasho, T. Danaparoid sodium attenuates the increase in inflammatory cytokines and preserves organ function inendotoxemic rats. Crit. Care 2008, 12, R86. [CrossRef]

Hagiwara,S.;Iwasaka,H.;Hidaka,S.;Hishiyama,S.; Noguchi,T.Danaparoidsodiuminhibitssystemicinfla mmationand prevents endotoxin-induced acute lung injury in rats. Crit. Care2008, 12, R43. [CrossRef]

Iba,T.;Kidokoro,A.;Fukunaga,M.;Nagakari,K.;Sud a,M.;Yoshikawa,S.;Ida,Y.Antithrombinameliorate sendotoxin-induced organdysfunctionmoreefficientlywhencombinedwi thdanaparoidsodiumthanwithunfractionatedheparin . IntensiveCare Med.2005, 31, 1101–1108. [CrossRef]

Myllylahti, L.; Pitkänen, H.; Magnani, H.; Lassila, R. Experience of danaparoid to treat vaccine-induced immune thrombocytopeniaand thrombosis, VITT. Thromb. J. 2022, 20, 4. [CrossRef]

Bertini, S.; Alekseeva, A.; Elli, S.; Pagani, I.; Zanzoni, S.; Eisele, G.; Krishnan, R.; Maag, K.P.; Reiter, C.; Lenhart, D.; et al. PentosanPolysulfate Inhibits Attachment and Infection by SARS-CoV-2 In Vitro: Insights into Structural Requirements for Binding. Thromb. Haemost.2022, 122, 984–997. [CrossRef]

Weiss,R.J.;Esko,J.D.;Tor,Y.Targetingheparinandhepar ansulfateproteininteractions.Org.Biomol.Chem.2017,15 ,5656–5668. [CrossRef]

Gallagher, J.T. Heparan sulphate:A heparin in miniature.InHeparin—A Century of Progress; Handbook of Experimental PharmacologyBookSeries;Springer: Berlin/Heidelberg,Germany,2012;pp. 347–360. [CrossRef]

Rudd, T.R.; Hughes, A.; Holman, J.; Solari, V.; Ferreira Ede, O.; Domingues, R.M.; Yates, E.A. Heparan sulphate, its derivatives and analogues share structural characteristics that can be exploited, particularly in inhibiting microbial attachment. Braz. J. Med. Biol. Res. 2012, 45, 386–391. [CrossRef]

Van Belkum, A.; Almeida, C.; Bardiaux, B.; Barrass, S.V.; Butcher, S.J.; Çaykara, T.; Chowdhury, S.; Datar, R.; Eastwood, I.; Goldman,A.;etal.Host- PathogenAdhesionastheBasisofInnovativeDiagnost icsforEmergingPathogens.Diagnostics2021,11, 1259. [CrossRef]

Sanchez, H.; Hopkins, D.; Demirdjian, S.; Gutierrez, C.; O’Toole, G.A.; Neelamegham, S.; Berwin, B. Identification of cell-surface glycansthatmediatemotilitydependentbindingandinternalizationofPseudomona saeruginosabyphagocytes. Mol.Immunol. 2021, 131, 68–77. [CrossRef]

Lorè, N.I.; Veraldi, N.; Riva, C.; Sipione, B.; Spagnuolo, L.; De Fino, I.; Melessike, M.; Calzi, E.; Bragonzi, A.; Naggi, A.; et al. Synthesized Heparan Sulfate Competitors Attenuate Pseudomonas aeruginosa Lung Infection.Int. J. Mol. Sci.2018,19, 207. [CrossRef]

Bucior, I.; Mostov, K.; Engel, J.N. Pseudomonas aeruginosa-mediated damage requires distinct receptors at the apical and basolateralsurfacesofthepolarizedepithelium. Infect.Immun.2010,78,939–953. [CrossRef]

Bucior, I.; Pielage, J.F.; Engel, J.N. Pseudomonasaeruginosapili and flagella mediate distinct binding and signaling events at the apicalandbasolateralsurfaceofairwayepithelium. PLoSPathog.2012,8,e1002616. [CrossRef]

Dzvova, N.; Colmer-Hamood, J.A.; Griswold, J.A.; Hamood, A.N. Heparinase Is Essential for Pseudomonas aeruginosa Virulence duringThermalInjuryandInfection. Infect.Immun.2018,86,e00755-17. [CrossRef]

Shi, H.; Tang, J.; An, C.; Yang, L.; Zhou, X. Protein A of Staphylococcus aureus strain NCTC8325 interacted with heparin.Arch. Microbiol.2021,203,2563–2573. [CrossRef]

Porayath,C.;Suresh,M.K.;Biswas,R.;Nair,B.G.;Mis hra,N.;Pal,S.AutolysinmediatedadherenceofStaphy lococcusaureuswith Fibronectin,GelatinandHeparin. Int. J.Biol. Macromol. 2018,110,179–184. [CrossRef][PubMed]

Hess,D.J.;Henry- Stanley,M.J.;Erlandsen,S.L.;Wells,C.L.Heparansu lfateproteoglycansmediateStaphylococcusaureus interactionswithintestinalepithelium.Med.Microbiol.Im munol.2006,195,133–141.[CrossRef][PubMed]

Seffer, M.T.; Eden, G.; Engelmann, S.; Kielstein, J.T. Elimination of Staphylococcus aureus from the bloodstream using a novel biomimeticsorbenthaemoperfusiondevice. BMJCaseRep.2020,13,e235262. [CrossRef][PubMed]

Eden,G.;Schmidt,J.J.;Büttner,S.;Kümpers,P.;Hafer, C.;Rovas,A.;Koch,B.F.;Schmidt,B.M.W.;Kielstein, J.T.Safetyandefficacy of the Seraph®100 Microbind®Affinity Blood Filter to remove bacteria from the blood stream: Results of the first in human study.Crit. Care 2022, 26, 181. [CrossRef]

Andermatt, R.; Bloemberg, G.V.; Ganter, C.C.; Mueller, N.J.; Mueller, A.M.S.; Muellhaupt, B.; Kielstein, J.T.; David, S. Elimination of Herpes Simplex Virus-2 and Epstein-Barr Virus With Seraph 100 Microbind Affinity Blood Filter and Therapeutic Plasma Exchange: An Explorative Study in a Patient With Acute Liver Failure. Crit. CareExplor. 2022, 4, e0745. [CrossRef]

Chen,L.;Kraft,B.D.;Roggli,V.L.;Healy,Z.R.;Woods,C .W.;Tsalik,E.L.;Ginsburg,G.S.;Murdoch,D.M.;Sulima n,H.B.;Piantadosi,C.A.; et al. Heparin-based blood purification attenuates organ injury in baboons with Streptococcus pneumoniae pneumonia. Am. J. Physiol. Lung Cell. Mol. Physiol. 2021, 321, L321– L335. [CrossRef]

Lin,G.L.;McGinley,J.P.;Drysdale,S.B.;Pollard,A.J.E pidemiologyandImmunePathogenesisofViralSepsis. Front.Immunol. 2018,9,2147.[CrossRef]

Kwizera, A.; Adhikari, N.K.J.; Angus, D.C.; Dondorp, A.M.; Dünser, M.W.; Festic, E.; Haniffa, R.; Kissoon, N.; Martin-Loeches, I.; Lundeg, G. Recognition of Sepsis in Resource-Limited Settings. In Sepsis Management in Resource-Limited Settings; Dondorp, A.M.,Dünser, M.W., Schultz, M.J., Eds.; Springer: Cham, Switzerland, 2019; pp. 69–84.

Monferrer,A.;Kretzmann,J.A.;Sigl,C.;Sapelza,P.;L iedl,A.;Wittmann,B.;Dietz,H.Broad- SpectrumVirusTrappingwith Heparan Sulfate- Modified DNA Origami Shells. ACSNano2022, 16, 20002–20009. [CrossRef]

Ancsin, J.B.; Kisilevsky, R. A binding site for highly sulfated heparan sulfate is identified in the N terminus of the circumsporozoiteprotein:Significance for malarial sporozoite attachment to hepatocytes.J. Biol. Chem. 2004, 279, 21824–21832.[CrossRef]

Kobayashi, K.; Kato, K.; Sugi, T.; Takemae, H.; Pandey, K.; Gong, H.; Tohya, Y.; Akashi, H. Plasmodium falciparum BAEBL binds toheparansulfateproteoglycansonthehumanerythro cytesurface.J.Biol.Chem.2010,285,1716– 1725.[CrossRef]

Leitgeb, A.M.; Charunwatthana, P.; Rueangveerayut, R.; Uthaisin, C.; Silamut, K.; Chotivanich, K.; Sila, P.; Moll, K.; Lee, S.J.; Lindgren, M.; etal. Inhibition ofmerozoite invasionandtransientde-sequestration bysevuparininhumans withPlasmodium falciparummalaria.PLoSONE2017,12,e0188754. [CrossRef]

Saiwaew,S.;Sritabal,J.;Piaraksa,N.;Keayarsa,S.;Ru engweerayut,R.;Utaisin,C.;Sila,P.;Niramis,R.;Udo msangpetch, R.; Charunwatthana, P.; et al.Effects of sevuparin on rosette formation and cytoadherence of Plasmodiumfalciparuminfected erythrocytes. PLoSONE2017,12,e0172718. [CrossRef]

Ventura-Santana, E.; Ninan, J.R.; Snyder, C.M.; Okeke, E.B. Neutrophil Extracellular Traps, Sepsis and COVID-19—A Tripod Stand.Front. Immunol. 2022,13,902206. [CrossRef]

Kearns, F.L.; Sandoval, D.R.; Casalino, L.; Clausen, T.M.; Rosenfeld, M.A.; Spliid, C.B.; Amaro, R.E.; Esko, J.D. Spike-heparan sulfateinteractionsinSARS-CoV-2infection. Curr.Opin.Struct.Biol.2022,76,102439. [CrossRef]

Parafioriti, M.; Ni, M.; Petitou, M.; Mycroft-West, C.J.; Rudd, T.R.; Gandhi, N.S.; Ferro, V.; Turnbull, J.E.; Lima, M.A.; Skidmore, M.A.; et al. Evidence for multiple binding modes in the initial contact between SARS-CoV-2 spike S1 protein and cell surface glycans.Chemistry2023,29,e202202599. [CrossRef]

Dwivedi, R.; Sharma, P.; Farrag, M.; Kim, S.B.; Fassero, L.A.; Tandon, R.; Pomin, V.H. Inhibition of SARS-CoV-2 wild-type (Wuhan-Hu- 1)andDelta(B.1.617.2)strainsbymarinesulfatedglyc ans.Glycobiology2022,32,849–854.[CrossRef]

Dwivedi,R.;Sharma,P.;Eilts,F.;Zhang,F.;Linhardt,R.J. ;Tandon,R.;Pomin,V.H.Anti-SARS-CoV- 2andanticoagulantpropertiesof Pentacta pygmaea fucosylated chondroitin sulfate depend on high molecular weight structures. Glycobiology 2022, 33, 75–85.[CrossRef]

Zhang, F.; He, P.; Rodrigues, A.L.; Jeske, W.; Tandon, R.; Bates, J.T.; Bierdeman, M.A.; Fareed, J.; Dordick, J.; Linhardt, R.J. PotentialAnti-SARS-CoV- 2ActivityofPentosanPolysulfateandMucopolysacchar idePolysulfate.Pharmaceuticals2022,15,258.[CrossR ef]

Shute, J.K.; Calzetta, L.; Cardaci, V.; di Toro, S.; Page, C.P.; Cazzola, M. Inhaled nebulisedunfractionated heparin improveslung function in moderate to very severe COPD: A pilot study. Pulm. Pharm. Ther. 2018, 48, 88–96. [CrossRef]

Calabretta, E.; Moraleda, J.M.; Iacobelli, M.; Jara, R.; Vlodavsky, I.; O’Gorman, P.; Pagliuca, A.; Mo, C.; Baron, R.M.; Aghemo, A.;etal.COVID-19- inducedendotheliitis:Emergingevidenceandpossible therapeuticstrategies.Br.J.Haematol.2021,193,43– 51. [CrossRef]

Eder, J.; Bermejo-Jambrina, M.; Vlaming, K.E.; Kaptein, T.M.; Zaderer, V.; Kemper, E.M.; Wilflingseder, D.; Reitsma, S.; deBree, G.J.; Cohn,D.M.;etal. InhalationofLowMolecularWeightHeparinsasProph ylaxisagainstSARS-CoV-2. mBio2022,13,e02558- 22. [CrossRef] [PubMed]

Bertanha, M.; Rodrigues, L.D.S.; Mellucci Filho, P.L.; Moroz, A.; Pardini, M.; Sobreira, M.L.; Durigon, E.L.; Machado, R.R.G.; Grotto,R.M.T.;Lima,M.A.;etal. Nebulizedenrichedheparintotreatnocriticalpatients withSARS-CoV-2: Triple-blindclinical trial.Medicine2021, 100, e28288. [CrossRef] [PubMed]

Jarczak,D.;Nierhaus,A.CytokineStorm- Definition,Causes,andImplications.Int.J.Mol.Sci.202 2,23,11740.[CrossRef] [PubMed]

Fajgenbaum,D.C.;June,C.H.CytokineStorm.N.Engl.J .Med.2020,383,2255–2273. [CrossRef][PubMed]

Hotchkiss,R.S.;Monneret,G.;Payen,D.Sepsisinducedimmunosuppression:Fromcellulardysfunctio nstoimmunotherapy. Nat.Rev.Immunol.2013,13,862–874.[CrossRef]

Farrugia, B.L.; Lord, M.S.; Melrose, J.; Whitelock, J.M. The Role of Heparan Sulfate in Inflammation, and the Development of BiomimeticsasAnti- InflammatoryStrategies.J.Histochem.Cytochem.20 18,66,321–336.[CrossRef]

Nguyen,K.G.;Gillam,F.B.;Hopkins,J.J.;Jayanthi,S.; Gundampati,R.K.;Su,G.;Bear,J.;Pilkington,G.R.;Ja lah,R.;Felber, B.K.;etal. Molecularmechanismsofheparininducedmodulationofhumaninterleukin12bioactivit y. J.Biol.Chem.2019,294, 4412–4424. [CrossRef]

Litov,L.;Petkov,P.;Rangelov,M.;Ilieva,N.;Lilkova, E.;Todorova,N.;Krachmarova,E.;Malinova,K.;Gos podinov,A.;Hristova, R.; et al. Molecular Mechanism of the Anti-Inflammatory Action of Heparin. Int. J.Mol. Sci. 2021, 22, 10730. [CrossRef]

Collins,L.E.;Troeberg,L.Heparansulfateasaregulator ofinflammationandimmunity.J.Leukoc.Biol.2019,10 5,81–92. [CrossRef]

Chousterman,B.G.;Swirski,F.K.;Weber,G.F.Cytoki nestormandsepsisdiseasepathogenesis. Semin. Immunopathol. 2017,39, 517–528. [CrossRef]

Shi, C.; Wang, C.; Wang, H.; Yang, C.; Cai, F.; Zeng, F.; Cheng, F.; Liu, Y.; Zhou, T.; Deng, B.; et al. The Potential of Low Molecular WeightHeparintoMitigateCytokineStorminSevereC OVID-19Patients: ARetrospectiveCohortStudy. Clin.Trans.Sci.2020, 13, 1087–1095. [CrossRef]

Liew,P.X.;Kubes,P.TheNeutrophil’sRoleDuringHealt handDisease.Physiol.Rev.2019,99,1223– 1248.[CrossRef]

Nathan,C.Neutrophilsandimmunity:Challengesando pportunities.Nat.Rev.Immunol.2006,6,173– 182.[CrossRef]

Papayannopoulos,V.Neutrophilextracellulartrapsinimm unityanddisease.Nat.Rev.Immunol.2018,18,134– 147.[CrossRef]

Semeraro, N.; Ammollo, C.T.; Semeraro, F.; Colucci, M. Sepsis-associated disseminated intravascular coagulation and thromboembolicdisease.Mediterr.J.Hematol.Infect.Dis.2 010,2,e2010024.[CrossRef]

Chang,J.C.Sepsisandsepticshock:Endothelialmolecul arpathogenesisassociatedwithvascularmicrothrombot icdisease. Thromb.J.2019,17,10.[CrossRef]

Beristain-Covarrubias, N.; Perez-Toledo, M.; Thomas, M.R.; Henderson, I.R.; Watson, S.P.; Cunningham, A.F. UnderstandingInfection- InducedThrombosis: LessonsLearnedFromAnimalModels. Front. Immunol. 2019,10,2569. [CrossRef]

Galli,E.;Maggio,E.;Pomero,F.VenousThromboembo lisminSepsis:FromBenchtoBedside.Biomedicines202 2,10,1651. [CrossRef]

Jaimes,F.;DeLaRosa,G.;Morales,C.;Fortich,F.;Ara ngo,C.;Aguirre,D.;Munoz,A.Unfractionedheparinf ortreatmentof sepsis: Arandomizedclinicaltrial(TheHETRASEStudy). Crit. CareMed. 2009,37,1185–1196. [CrossRef]

Voynow, J.A.; Zheng, S.; Kummarapurugu, A.B. Glycosaminoglycans as Multifunctional Anti- Elastase and Anti-Inflammatory Drugs in Cystic Fibrosis Lung Disease. Front. Pharm. 2020, 11, 1011. [CrossRef]

Juschten,J.;Tuinman,P.R.;Juffermans,N.P.;Dixon,B.; Levi,M.;Schultz,M.J.Nebulizedanticoagulantsinlungi njuryincriticallyill patients—An updated systematic review of preclinical and clinical studies.Ann. Transl. Med. 2017, 5, 444.[CrossRef] [PubMed]

Bazzoni,G.;BeltranNunez,A.;Mascellani,G.;Bianc hini,P.;Dejana,E.;DelMaschio,A.Effectofheparin,d ermatansulfate,and relatedoligoderivativesonhumanpolymorphonuclearleukocytef unctions. J.Lab.Clin.Med.1993,121,268–275. [PubMed]

Brown,R.A.;Lever,R.;Jones,N.A.;Page,C.P.Effectsof heparinandrelatedmoleculesuponneutrophilaggregati onandelastaserelease in vitro. Br. J. Pharm. 2003, 139, 845–853. [CrossRef] [PubMed]

Freischlag,J.A.; Colburn, M.D.; Quinones-Baldrich, W.J.; Moore, W.S. Heparin, urokinase, and ancrod alter neutrophil function.J. Vasc. Surg. 1992, 16, 565–572. [CrossRef]

Laghi Pasini, F.; Pasqui, A.L.; Ceccatelli, L.; Capecchi, P.L.; Orrico, A.; Di Perri, T. Heparin inhibition of polymorphonuclear leukocyte activation in vitro.A possible pharmacological approach to granulocyte-mediated vascular damage.Thromb. Res. 1984,35, 527–537. [CrossRef]

Piccardoni,P.;Evangelista,V.;Piccoli,A.;deGaetano ,G.;Walz,A.;Cerletti,C.Thrombinactivatedhumanplateletsreleasetwo NAP- 2variantsthatstimulatepolymorphonuclearleukocyt es. Thromb.Haemost.1996,76,780–785. [CrossRef]

Skinner,M.P.;Lucas,C.M.;Burns,G.F.;Chesterman, C.N.;Berndt,M.C.GMP- 140bindingtoneutrophilsisinhibitedbysulfated glycans.J.Biol. Chem. 1991,266,5371–5374. [CrossRef]

Koenig, A.; Norgard-Sumnicht, K.; Linhardt, R.; Varki, A. Differential interactions of heparin and heparan sulfate glycosamino-glycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J. Clin. Investig. 1998, 101, 877–889. [CrossRef]

Page, C.; Pitchford, S. Neutrophil and platelet complexes and their relevance to neutrophil recruitment and activation.Int. Immunopharmacol.2013,17,1176–1184.[CrossRef]

Kornerup, K.N.; Salmon, G.P.; Pitchford, S.C.; Liu, W.L.; Page, C.P. Circulating plateletneutrophil complexes are important for subsequentneutrophilactivationandmigration. J.Appl.Physiol.2010,109,758–767. [CrossRef]

Clark, S.R.; Ma, A.C.; Tavener, S.A.; McDonald, B.; Goodarzi, Z.; Kelly, M.M.; Patel, K.D.; Chakrabarti, S.; McAvoy, E.; Sinclair,G.D.; et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat. Med. 2007, 13, 463–469.[CrossRef]

Caudrillier,A.;Kessenbrock,K.;Gilliss,B.M.;Nguye n,J.X.;Marques,M.B.;Monestier,M.;Toy,P.;Werb,Z .;Looney,M.R.Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury.J. Clin.Investig.2012, 122, 2661– 2671.[CrossRef]

Ley,K.;Cerrito,M.;Arfors,K.E.Sulfatedpolysaccharid esinhibitleukocyterollinginrabbitmesenteryvenules.A m.J.Physiol. 1991, 260,H1667–H1673.[CrossRef]

Giuffre,L.;Cordey,A.S.;Monai,N.;Tardy,Y.;Schapi ra,M.;Spertini,O.Monocyteadhesiontoactivatedaort icendothelium: Role ofL- selectinandheparansulfateproteoglycans. J.CellBiol. 1997,136,945–956. [CrossRef]

Bonfanti, R.; Furie, B.C.; Furie, B.; Wagner, D.D. PADGEM (GMP140) is a component of Weibel- Palade bodies of human endothelialcells.Blood 1989, 73, 1109–1112. [CrossRef]

Lorant,D.E.;Topham,M.K.;Whatley,R.E.;McEver, R.P.;McIntyre,T.M.;Prescott,S.M.;Zimmerman,G. A.Inflammatoryrolesof P-selectin. J.Clin. Investig. 1993,92,559–570. [CrossRef]

Wang,L.;Brown,J.R.;Varki,A.;Esko,J.D.Heparin’s anti-inflammatoryeffectsrequireglucosamine6-O- sulfationandare mediatedbyblockadeofL-andP- selectins. J.Clin. Investig. 2002,110,127–136. [CrossRef]

Hostettler, N.; Naggi, A.; Torri, G.; Ishai- Michaeli, R.; Casu, B.; Vlodavsky, I.; Borsig, L. P-selectin- and heparanase-dependent antimetastaticactivityofnonanticoagulantheparins.FASEBJ.2007,21,3562– 3572.[CrossRef]

Riffo-Vasquez, Y.;Somani, A.;Man, F.; Amison,R.; Pitchford, S.; Page, C.P.ANon- AnticoagulantFractionofHeparinInhibits LeukocyteDiapedesisintotheLungbyanEffectonPlatel ets.Am.J. Respir.Cell Mol.Biol.2016,55,554– 563.[CrossRef]

Maugeri, N.; Di, F.G.; Barbanti, M.; de Gaetano, G.; Donati, M.B.; Cerletti, C. Parnaparin, a lowmolecular-weight heparin, preventsP-selectindependentformationofplateletleukocyteaggregatesinhumanwholeblood.Thromb. Haemost. 2007, 97, 965–973.

Ley, K.; Laudanna, C.; Cybulsky, M.I.; Nourshargh, S. Getting to the site of inflammation: The leukocyte adhesion cascade updated.Nat. Rev. Immunol. 2007,7,678–689. [CrossRef][PubMed]

Massena, S.; Christoffersson, G.; Hjertstrom, E.; Zcharia, E.; Vlodavsky, I.; Ausmees, N.; Rolny, C.; Li, J.P.; Phillipson, M. A chemotactic gradient sequestered on endothelial heparan sulfate induces directional intraluminal crawling of neutrophils. Blood 2010, 116, 1924–1931. [CrossRef] [PubMed]

Lever, R.; Lo, W.T.; Faraidoun, M.; Amin, V.; Brown, R.A.; Gallagher, J.; Page, C.P. Sizefractionated heparins have differential effectsonhumanneutrophilfunctioninvitro. Br. J.Pharm. 2007,151,837–843. [CrossRef][PubMed]

Veraldi, N.; Hughes, A.J.; Rudd, T.R.; Thomas, H.B.; Edwards, S.W.; Hadfield, L.; Skidmore, M.A.; Siligardi, G.; Cosentino, C.; Shute, J.K.; et al. Heparin derivatives for the targeting of multiple activities in the inflammatory response. Carbohydr. Polym. 2015,117, 400–407. [CrossRef]

Redini, F.; Tixier, J.M.; Petitou, M.; Choay, J.; Robert, L.; Hornebeck, W. Inhibition of leucocyte elastase by heparin and its derivatives.Biochem. J.1988, 252, 515–519. [CrossRef]

Lahrsen,E.;Schoenfeld,A.K.;Alban,S.Degradation ofEightSulfatedPolysaccharidesExtractedfromRed andBrownAlgaeand ItsImpactonStructureandPharmacologicalActivitie s. ACSBiomater.Sci.Eng.2019,5,1200–1214. [CrossRef]

Massberg, S.; Grahl, L.; von Bruehl, M.L.; Manukyan, D.; Pfeiler, S.; Goosmann, C.; Brinkmann, V.; Lorenz, M.; Bidzhekov, K.; Khandagale,A.B.;etal.Reciprocalcouplingofcoagul ationandinnateimmunityvianeutrophilserineproteas es.Nat.Med.2010, 16, 887–896. [CrossRef]

Marchetti, M.; Falanga, A. Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders.Pathophysiol. Haemost.Thromb.2008,36,148–159. [CrossRef]

Rasmuson,J.;Kenne,E.;Wahlgren,M.;Soehnlein,O.; Lindbom,L.HeparinoidsevuparininhibitsStreptococ cus-inducedvascular leakthroughneutralizingneutrophilderivedproteins.FASEBJ.2019,33,10443– 10452.[CrossRef]

Fisher,J.;Linder,A.Heparinbindingprotein:Akeyplayerinthepathophysiologyofor gandysfunctioninsepsis.J.Intern.Med. 2017,281,562–574.[CrossRef]

Kaplan, M.J.; Radic, M. Neutrophil extracellular traps: Double-edged swords of innate immunity. J.Immunol. 2012, 189, 2689–2695.[CrossRef]

Brinkmann, V.; Reichard, U.; Goosmann, C.; Fauler, B.; Uhlemann, Y.; Weiss, D.S.; Weinrauch, Y.; Zychlinsky, A. Neutrophil extracellulartrapskillbacteria.Science2004,303,153 2–1535.[CrossRef]

Urban, C.F.; Ermert, D.; Schmid, M.; Abu-Abed, U.; Goosmann, C.; Nacken, W.; Brinkmann, V.; Jungblut, P.R.; Zychlinsky, A. Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans.PLoSPathog. 2009,5,e1000639. [CrossRef]

Hakkim, A.; Furnrohr, B.G.; Amann, K.; Laube, B.; Abed, U.A.; Brinkmann, V.; Herrmann, M.; Voll, R.E.; Zychlinsky, A. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis.Proc. Natl. Acad. Sci. USA2010, 107,9813–9818. [CrossRef]

Gupta, A.K.; Hasler, P.; Holzgreve, W.; Gebhardt, S.; Hahn, S. Induction of neutrophil extracellular DNA lattices by placentalmicroparticlesandIL- 8andtheirpresenceinpreeclampsia.Hum.Immunol.2 005,66,1146–1154.[CrossRef]

Kessenbrock,K.;Krumbholz,M.;Schonermarck,U.; Back,W.;Gross,W.L.;Werb,Z.;Grone,H.J.;Brinkma nn,V.;Jenne,D.E. Nettingneutrophilsinautoimmunesmallvesselvasculitis. Nat. Med. 2009,15,623–625. [CrossRef]

Delgado-Rizo, V.; Martinez-Guzman, M.A.; Iniguez-Gutierrez, L.; Garcia-Orozco, A.; Alvarado-Navarro, A.; Fafutis-Morris, M.Neutrophil Extracellular Traps and Its Implications in Inflammation: An Overview. Front. Immunol. 2017, 8, 81. [CrossRef]

Long, Y.; Zhang, Y.; Gong, Y.; Sun, R.; Su, L.; Lin, X.; Shen, A.; Zhou, J.; Caiji, Z.; Wang, X.; et al.Diagnosis of Sepsis with Cell-free DNA by Next-Generation Sequencing Technology in ICU Patients. Arch. Med. Res. 2016, 47, 365–371. [CrossRef]

Alhamdi,Y.;Abrams,S.T.;Cheng,Z.;Jing,S.;Su,D.; Liu,Z.;Lane,S.;Welters,I.;Wang,G.;Toh,C.H.Circul atingHistonesAre MajorMediatorsofCardiacInjuryinPatientsWithSep sis. Crit.CareMed.2015,43,2094–2103. [CrossRef]

Saukkonen,K.;Lakkisto,P.;Pettila,V.;Varpula,M.;K arlsson,S.;Ruokonen,E.;Pulkki,K.;FinnsepsisStudy ,G.Cell-freeplasma DNAasapredictorofoutcomeinseveresepsisandsepti cshock. Clin. Chem. 2008,54,1000–1007. [CrossRef]

Rhodes,A.;Cecconi,M.CellfreeDNAandoutcomeinsepsis.Crit.Care2012,16,170. [CrossRef] [PubMed]

Fuchs,T.A.;Brill,A.;Duerschmied,D.;Schatzberg,D.; Monestier,M.;Myers,D.D.,Jr.;Wrobleski,S.K.;Wakefi eld,T.W.;Hartwig,J.H.; Wagner, D.D. Extracellular DNA traps promote thrombosis. Proc. Natl. Acad. Sci. USA 2010, 107, 15880–15885. [CrossRef][PubMed]

Napirei, M.; Ludwig, S.; Mezrhab, J.; Klockl, T.; Mannherz, H.G. Murine serum nucleases— Contrasting effects of plasmin and heparinontheactivitiesofDNase1andDNase1- like3(DNase1l3). FEBSJ.2009,276,1059–1073. [CrossRef][PubMed]

Brill, A.; Fuchs, T.A.; Savchenko, A.S.; Thomas, G.M.; Martinod, K.; De Meyer, S.F.; Bhandari, A.A.; Wagner, D.D. Neutrophil extracellulartrapspromotedeepveinthrombosisinmi ce.J.Thromb.Haemost.2012,10,136– 144.[CrossRef]

Varju,I.;Longstaff,C.;Szabo,L.;Farkas,A.Z.;Varga- Szabo,V.J.;Tanka- Salamon,A.;Machovich,R.;Kolev,K.DNA,histones and neutrophil extracellular traps exert antifibrinolytic effects in a plasma environment. Thromb. Haemost. 2015, 113, 1289–1298.[CrossRef]

Komorowicz, E.;Balázs,N.;Tanka- Salamon,A.;Varga,Z.;Szabó,L.;Bóta,A.;Longstaff, C.;Kolev,K.Size-andcharge-dependent modulationofthelyticsusceptibilityandmechanicalst abilityoffibrinhistoneclotsbyheparinandpolyphosphatevariants. J. Thromb.Haemost.2021,19,1307–1318.[CrossRef]

Longstaff,C.;Hogwood,J.;Gray,E.;Komorowicz,E.; Varjú,I.;Varga,Z.;Kolev,K.Neutralisationoftheanticoagulanteffectsof heparinbyhistonesinbloodplasmaandpurifiedsyste ms. Thromb.Haemost.2016,115,591–599. [CrossRef]

Hogwood, J.; Pitchford, S.; Mulloy, B.; Page, C.; Gray, E. Heparin and non-anticoagulant heparin attenuate histone-induced inflammatoryresponsesinwholeblood. PLoSONE2020,15,e0233644. [CrossRef]

Sharma, N.; Haggstrom, L.; Sohrabipour, S.; Dwivedi, D.J.; Liaw, P.C. Investigations of the effectiveness of heparin variants as inhibitorsofhistones.J.Thromb.Haemost.2022,20,1 485–1495.[CrossRef]

Wildhagen,K.C.;GarciadeFrutos,P.;Reutelingsperg er,C.P.;Schrijver,R.;Areste,C.;Ortega- Gomez,A.;Deckers,N.M.;Hemker, H.C.; Soehnlein, O.; Nicolaes, G.A. Nonanticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves survivalinsepsis. Blood2014,123,1098–1101. [CrossRef]

Yang,X.;Li,L.;Liu,J.;Lv,B.;Chen,F.Extracellularhisto nesinducetissuefactorexpressioninvascularendothelial cellsviaTLRand activation of NF-kappaB and AP- 1.Thromb.Res.2016, 137, 211–218.[CrossRef]

Gould, T.J.; Lysov, Z.; Swystun, L.L.; Dwivedi, D.J.; Zarychanski, R.; Fox-Robichaud, A.E.; Liaw, P.C.; Canadian Critical Care TranslationalBiology,G.ExtracellularHistonesIncre aseTissueFactorActivityandEnhanceThrombinGen erationbyHuman Blood Monocytes. Shock2016, 46, 655–662. [CrossRef]

Ekaney,M.L.;Otto,G.P.;Sossdorf,M.;Sponholz,C.; Boehringer,M.;Loesche,W.;Rittirsch,D.;Wilharm, A.;Kurzai,O.;Bauer,M.; etal. Impactofplasmahistonesinhumansepsisandtheircon tributiontocellularinjuryandinflammation. Crit.Care2014,18, 543.[CrossRef]

Freeman, C.G.; Parish, C.R.; Knox, K.J.; Blackmore, J.L.; Lobov, S.A.; King, D.W.; Senden, T.J.; Stephens, R.W. The accumulation ofcirculatinghistonesonheparansulphateinthecapillary glycocalyxofthelungs.Biomaterials 2013,34,5670– 5676.[CrossRef]

Zhu,C.;Liang,Y.;Li,X.;Chen,N.;Ma,X.Unfractiona tedheparinattenuateshistonemediatedcytotoxicityinvitroandprevents intestinalmicrocirculatorydysfunctioninhistoneinfusedrats.J.TraumaAcuteCare2019,87,614– 622.[CrossRef]

Fabian,I.;Aronson,M.Polycationsaspossiblesubstitutesf orprotamineinheparinneutralization.Thromb.Res.1980, 17,239–247. [CrossRef]

Pal,P.K.;Starr,T.;Gertler,M.M.Neutralizationofheparin byhistoneanditssubfractions.Thromb.Res.1983,31,69– 79.[CrossRef]

Wang, F.; Zhang, N.; Li, B.; Liu, L.; Ding, L.; Wang, Y.; Zhu, Y.; Mo, X.; Cao, Q. Heparin defends against the toxicity of circulating histonesinsepsis.Front.Biosci.LandmarkEd.2015,2 0,1259–1270.

Mandel,J.;Casari,M.;Stepanyan,M.;Martyanov,A.; Deppermann,C.BeyondHemostasis: PlateletInnateImmuneInteractions and Thromboinflammation. Int. J.Mol. Sci. 2022, 23, 3868. [CrossRef]

Chen,Z.;Zhang,H.;Qu,M.;Nan,K.;Cao,H.;Cata,J.P. ;Chen,W.;Miao,C.Review:TheEmergingRoleofNe utrophil ExtracellularTrapsinSepsisandSepsis- AssociatedThrombosis.Front.CellInfect.Microbiol. 2021,11,653228.[CrossRef]

Jiao,Y.;Li,W.;Wang,W.;Tong,X.;Xia,R.;Fan,J.;Du, J.;Zhang,C.;Shi,X.Plateletderivedexosomespromoteneutrophil extracellular trap formation during septic shock. Crit. Care2020, 24, 380. [CrossRef] [PubMed]

McDonald, B.; Davis, R.P.; Kim, S.-J.; Tse, M.; Esmon, C.T.; Kolaczkowska, E.; Jenne, C.N. Platelets and neutrophil extracellular trapscollaboratetopromoteintravascularcoagulationdu ringsepsisinmice.Blood 2017,129,1357– 1367.[CrossRef][PubMed]

Yuan, F.; Yang, Y.; Zhou, H.; Quan, J.; Liu, C.; Wang, Y.; Zhang, Y.; Yu, X. Heparanase in cancer progression: Structure, substrate recognitionandtherapeuticpotential. Front.Chem.2022,10,926353. [CrossRef][PubMed]

Masola,V.;Greco,N.;Gambaro,G.;Franchi,M.;Onisto ,M.Heparanaseasactiveplayerinendothelialglycocaly xremodeling. MatrixBiol.Plus2022,13, 100097.[CrossRef][PubMed]

Sullivan, R.C.; Rockstrom, M.D.; Schmidt, E.P.; Hippensteel, J.A. Endothelial glycocalyx degradation during sepsis: Causes and consequences. MatrixBiol.Plus2021,12,100094. [CrossRef]

Drost,C.C.;Rovas,A.;Kümpers,P.Protectionandrebuil dingoftheendothelialglycocalyxinsepsis— Scienceorfiction?Matrix Biol. Plus 2021, 12, 100091. [CrossRef]

Oshima,K.;King,S.I.;McMurtry,S.A.;Schmidt,E.P. EndothelialHeparanSulfateProteoglycansinSepsis: TheRoleofthe Glycocalyx.Semin. Thromb. Hemost. 2021,47,274–282. [CrossRef]

Goligorsky,M.S.;Sun,D.GlycocalyxinEndotoxemiaa ndSepsis.Am.J.Pathol.2020,190,791–798.[CrossRef]

Kiyan,Y.;Tkachuk,S.;Kurselis,K.;Shushakova,N.; Stahl,K.;Dawodu,D.;Kiyan,R.;Chichkov,B.;Haller, H.Heparanase-2 protectsfromLPS- mediatedendothelialinjurybyinhibitingTLR4signall ing. Sci. Rep. 2019,9,13591. [CrossRef]

Freeman,C.;Parish,C.R.Humanplateletheparanase: Purification,characterizationandcatalyticactivity. Biochem.J.1998,330 Pt 3, 1341–1350. [CrossRef]

Sanderson, R.D.; Yang, Y.; Suva, L.J.; Kelly, T. Heparan sulfate proteoglycans and heparanase— Partners in osteolytic tumorgrowthandmetastasis. MatrixBiol. 2004,23,341–352. [CrossRef]

Lindahl, U.; Li,J.P. Heparanase—Discovery andTargets.Adv.Exp.Med.Biol.2020,1221, 61– 69.[CrossRef]

Gong,F.;Jemth,P.;EscobarGalvis,M.L.;Vlodavsky,I.; Horner,A.;Lindahl,U.;Li,J.P.Processingofmacromole cularheparinbyheparanase.J. Biol. Chem. 2003, 278, 35152–35158. [CrossRef]

Ilan,N.;Elkin,M.;Vlodavsky,I.Regulation,functionandcl inicalsignificanceofheparanaseincancermetastasisandan giogenesis. Int.J.Biochem.CellBiol.2006,38,2018–2039.[CrossRef]

Eustes,A.S.; Campbell,R.A.; Middleton,E.A.; Tolley,N.D.; Manne,B.K.; Montenont,E.; Rowley,J.W.; Krauel,K.; Blair,A.; Guo,L.; et al. Heparanase expression and activity are increased in platelets during clinical sepsis. J.Thromb. Haemost. 2021, 19, 1319–1330.[CrossRef]

Vlodavsky, I.; Barash, U.; Nguyen, H.M.; Yang, S.M.; Ilan, N. Biology of the Heparanase-Heparan Sulfate Axis and Its Role in DiseasePathogenesis. Semin.Thromb.Hemost.2021,47,240–253. [CrossRef]

Goodall,K.J.;Poon,I.K.;Phipps,S.;Hulett,M.D.Solu bleheparansulfatefragmentsgeneratedbyheparanase triggertherelease ofproinflammatorycytokinesthroughTLR-4. PLoSONE2014,9,e109596. [CrossRef]

Schmidt, E.P.; Yang, Y.; Janssen, W.J.; Gandjeva, A.; Perez, M.J.; Barthel, L.; Zemans, R.L.; Bowman, J.C.; Koyanagi, D.E.; Yunt,Z.X.; et al. The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. Nat. Med.2012, 18, 1217– 1223. [CrossRef]

Li, J.; Qi, Z.; Li, D.; Huang, X.; Qi, B.; Feng, J.; Qu, J.; Wang, X. Alveolar epithelial glycocalyx shedding aggravates the epithelial barrieranddisruptsepithelialtightjunctionsinacuteres piratorydistresssyndrome.Biomed.Pharmacother.2 021,133,111026. [CrossRef]

Lygizos, M.I.; Yang, Y.; Altmann, C.J.; Okamura, K.; Hernando, A.A.; Perez, M.J.; Smith, L.P.; Koyanagi, D.E.; Gandjeva, A.;Bhargava,R.;etal.Heparanasemediatesrenaldysfun ctionduringearlysepsisinmice.Physiol.Rep.2013,1,e00 153.[CrossRef]

Chen,S.;Zhang,X.;Sun,Y.;Hu,Z.;Lu,S.;Ma,X.Unfracti onatedheparinattenuatesintestinalinjuryinmousemode lofsepsisbyinhibiting heparanase. Int. J. Clin. Exp. Pathol. 2015, 8, 4903–4912. [PubMed]

Chen, S.; He, Y.; Hu, Z.; Lu, S.; Yin, X.; Ma, X.; Lv, C.; Jin, G. Heparanase Mediates Intestinal Inflammation and Injury in a Mouse ModelofSepsis. J.Histochem. Cytochem. 2017,65,241–249. [CrossRef][PubMed]

Tang,Y.;Wang,X.;Li,Z.;He,Z.;Yang,X.;Cheng,X.;P eng,Y.;Xue,Q.;Bai,Y.;Zhang,R.;etal.Heparinpreve ntscaspase-11- dependentsepticlethalityindependentofanticoagulan tproperties.Immunity2021,54,454– 467.e456.[CrossRef][PubMed]

Zhang, X.; Han, X.; Xia, K.; Xu, Y.; Yang, Y.; Oshima, K.; Haeger, S.M.; Perez, M.J.; McMurtry, S.A.; Hippensteel, J.A.; et al. Circulatingheparinoligosaccharidesrapidlytargetthe hippocampusinsepsis,potentiallyimpactingcognitiv efunctions. Proc. Natl.Acad.Sci.USA2019,116,9208–9213. [CrossRef]

Hippensteel, J.A.; Anderson, B.J.; Orfila, J.E.; McMurtry, S.A.; Dietz, R.M.; Su, G.; Ford, J.A.; Oshima, K.; Yang, Y.; Zhang, F.; et al. Circulatingheparansulfatefragmentsmediatesepticc ognitivedysfunction. J.Clin.Investig.2019,129,1779–1784. [CrossRef]

Mohamed,S.;Coombe,D.R.HeparinMimetics:TheirTher apeuticPotential.Pharmaceuticals2017,10,78.[CrossRef ]

Cassinelli,G.;Torri,G.;Naggi,A.Non- AnticoagulantHeparinsasHeparanaseInhibitors.A dv.Exp.Med.Biol.2020,1221, 493– 522.[CrossRef]

Noseda, A.; Barbieri, P.Roneparstat: Development, PreclinicalandClinicalStudies.Adv. Exp. Med. Biol. 2020, 1221, 523–538. [CrossRef]

Buijsers, B.; Yanginlar, C.; de Nooijer, A.; Grondman, I.; Maciej-Hulme, M.L.; Jonkman, I.; Janssen, N.A.F.; Rother, N.; de Graaf, M.; Pickkers, P.; et al. Increased Plasma Heparanase Activity in COVID-19 Patients. Front. Immunol. 2020, 11, 575047. [CrossRef]

Xiang,J.;Lu,M.;Shi,M.;Cheng,X.;Kwakwa,K.A.;D avis,J.L.;Su,X.;Bakewell,S.J.;Zhang,Y.;Fontana,F. ;etal.Heparanase Blockade as a Novel Dual- Targeting Therapy for COVID-19. J.Virol. 2022, 96, e0005722. [CrossRef]

Chhabra, M.; Wilson, J.C.; Wu, L.; Davies, G.J.; Gandhi, N.S.; Ferro, V. Structural Insights into Pixatimod (PG545) Inhibition of Heparanase,aKeyEnzymeinCancerandViralInfecti ons. Chemistry2022,28,e202104222. [CrossRef]

Guimond,S.E.;Mycroft- West,C.J.;Gandhi,N.S.;Tree,J.A.;Le,T.T.;Spalluto, C.M.;Humbert,M.V.;Buttigieg,K.R.;Coombes, N.; Elmore, M.J.; et al. Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 by Disrupting the Spike-ACE2 Interaction. ACSCent. Sci. 2022, 8, 527–545. [CrossRef]

Kinaneh, S.; Khamaysi, I.; Karram, T.; Hamoud, S. Heparanase as a potential player in SARS-CoV- 2 infection and induced coagulopathy. Biosci.Rep.2021,41,BSR20210290. [CrossRef]

Li,X.;Ma,X.Theroleofheparininsepsis:Muchmoretha njustananticoagulant.Br.J.Haematol.2017,179,389– 398.[CrossRef]

Murao,S.;Yamakawa,K.ASystematicSummaryofSy stematicReviewsonAnticoagulantTherapyinSepsis. J.Clin.Med.2019,8, 1869. [CrossRef]

Galli, M.; Chatterjee, M.; Grasso, M.; Specchia, G.; Magen, H.; Einsele, H.; Celeghini, I.; Barbieri, P.; Paoletti, D.; Pace, S.; et al. Phase I study of the heparanase inhibitor roneparstat: An innovative approach for ultiple myeloma therapy. Haematologica 2018,103, e469–e472. [CrossRef]

Biemond, B.J.; Tombak, A.; Kilinc, Y.; Al- Khabori, M.; Abboud, M.; Nafea, M.; Inati, A.; Wali, Y.; Kristensen, J.; Kowalski, J.; et al. Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: A multicentre, randomised, double-blind, placebocontrolled,phase2trial.LancetHaematol.2021,8,e33 4–e343.[CrossRef]

Dredge, K.; Brennan, T.V.; Hammond, E.; Lickliter, J.D.; Lin, L.; Bampton, D.; Handley, P.; Lankesheer, F.; Morrish, G.; Yang, Y.;etal. APhaseIstudyofthenovelimmunomodulatoryagentP G545(pixatimod)insubjectswithadvancedsolidtumo urs. Br.J. Cancer2018,118,1035–1041. [CrossRef]

Downloads

Published

2026-06-22